FGFR3 Fusions Erdafitinib — SCE Medical Oncology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Serial serum phosphate plus ophthalmic monitoring for central serous retinopathy
Erdafitinib characteristically raises serum phosphate and can cause central serous retinopathy, requiring serial phosphate and scheduled ophthalmic monitoring. Serial serum phosphate plus echocardiography for left-ventricular dysfunction: phosphate is relevant, but erdafitinib requires retinal rather than routine cardiac surveillance. Serial serum calcium plus ophthalmic monitoring for central serous retinopathy: the characteristic pharmacodynamic electrolyte is phosphate rather than calcium. Serial serum phosphate plus audiometry for high-frequency hearing loss: ototoxicity is not the paired organ toxicity of FGFR inhibition. Serial serum magnesium plus ophthalmic monitoring for central serous retinopathy: magnesium does not provide the pharmacodynamic titration signal.
Reference: Balversa 3 mg UK summary of product characteristics (Current UK SmPC, updated June 2026): https://www.medicines.org.uk/emc/product/100244/smpc; NICE TA1062 erdafitinib: recommendations (Published 2025; current NICE TA): https://www.nice.org.uk/guidance/ta1062/chapter/1-Recommendations